These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11176962)

  • 1. Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.
    Friess E; Kuempfel T; Winkelmann J; Schmid D; Uhr M; Rupprecht R; Holsboer F; Trenkwalder C
    Arch Neurol; 2001 Feb; 58(2):241-6. PubMed ID: 11176962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
    Llau ME; Durrieu G; Tran MA; Senard JM; Rascol O; Montastruc JL
    Clin Neuropharmacol; 1996 Oct; 19(5):420-7. PubMed ID: 8889285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone response to low-dose apomorphine in restless legs syndrome.
    Happe S; Bachmann CG; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Growth Horm IGF Res; 2007 Aug; 17(4):323-7. PubMed ID: 17512770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute challenge with apomorphine and levodopa in Parkinsonism.
    Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
    Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multihormonal responses to apomorphine in mental illness.
    Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
    Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.
    Pellecchia MT; Pivonello R; Salvatore E; Faggiano A; Barone P; De Michele G; Lombardi G; Colao A; Filla A
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):428-33. PubMed ID: 15807873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms.
    Pellecchia MT; Longo K; Manfredi M; Lucetti C; Cossu G; Petrone A; Marconi R; Sensi M; Epifanio A; Eleopra R; Marchese R; Scaravilli T; Morgante L; Abbruzzese G; Bonuccelli U; Donati E; Pivonello R; Colao A; Barone P
    Mov Disord; 2008 Jan; 23(2):190-4. PubMed ID: 18044703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy.
    Schaefer S; Vogt T; Nowak T; Kann PH;
    J Neuroendocrinol; 2008 Jan; 20(1):104-9. PubMed ID: 18081558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in multihormonal responses to the dopamine agonist apomorphine between unipolar and bipolar depressed patients.
    Monreal JA; Duval F; Mokrani MC; Fattah S; Palao D
    J Psychiatr Res; 2019 May; 112():18-22. PubMed ID: 30836201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
    Zhang K; Zeng Y; Song C; Fu Y; Wan Q
    J Neurol; 2010 Sep; 257(9):1486-91. PubMed ID: 20405138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F; Bellodi L; Perna G; Arancio C; Bertani A
    Biol Psychiatry; 1997 Nov; 42(10):889-97. PubMed ID: 9359974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
    Rouco I; Gómez JC; Lezcano E; Aniel-Quiroga MA; Velasco F; Barcena J; Pérez Bas M; Hurtado P; Cruz Lachén M; Zarranz JJ
    Neurologia; 2006 Apr; 21(3):119-23. PubMed ID: 16575624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers.
    Miell JP; Corder R; Pralong FP; Gaillard RC
    J Clin Endocrinol Metab; 1991 Mar; 72(3):675-81. PubMed ID: 1671785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.
    Delva NJ; Brooks DL; Franklin M; al-Said K; Hawken ER; Merali Z; Lawson JS; Ravindran AV
    J Psychiatry Neurosci; 2002 Nov; 27(6):429-37. PubMed ID: 12491576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.
    Happe S; Tings T; Koch W; Welsch J; Helmschmied K; Baier PC; Meller J; Wuttke W; Paulus W; Tatsch K; Trenkwalder C
    J Neural Transm (Vienna); 2007; 114(5):589-94. PubMed ID: 17187291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease.
    Kompoliti K; Wang QE; Goetz CG; Leurgans S; Raman R
    Neurology; 2000 Jan; 54(2):458-62. PubMed ID: 10668714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine responses to levodopa in multiple system atrophy (MSA).
    Kimber J; Watson L; Mathias CJ
    Mov Disord; 1999 Nov; 14(6):981-7. PubMed ID: 10584673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.